Vaccines of preferential administration via mucous membranes, for the control of viral diseases generated by infectious agents that use heparan sulfate (HS) as a cellular receptor consisting of an immunogenic formulation for veterinary use, comprising an antigen whose cellular receptor is heparan sulfate (HS), a vehicle for oral, intranasal or parenteral administration, wherein said vehicle corresponds to D-glucosamine and functionalized N-acetyl-D-glucosamine biopolymers, with sulfur atoms, and/or functionalized chitosan biopolymer, with sulfur atoms, and where the antigen is microencapsulated by said types of functionalized biopolymers.

A vaccine composition includes a porcine epidemic diarrhea virus (PEDV) S1 spike protein having an amino acid sequence of SEQ ID NO: 1, and an inactivated porcine epidemic diarrhea virus (PEDV). The vaccine composition is used in a method of preventing PEDV infection in swine, whereby systemic Immunoglobulin G (IgG), Immunoglobulin A (IgA) and neutralizing antibody may be successfully induced by the vaccine composition, hence providing sufficient immune protection against PEDV.

A vaccine composition includes a porcine epidemic diarrhea virus (PEDV) S1 spike protein having an amino acid sequence of SEQ ID NO: 1, and an inactivated porcine epidemic diarrhea virus (PEDV). The vaccine composition is used in a method of preventing PEDV infection in swine, whereby systemic Immunoglobulin G (IgG), Immunoglobulin A (IgA) and neutralizing antibody may be successfully induced by the vaccine composition, hence providing sufficient immune protection against PEDV.

Disclosed are methods and compositions related to the use cannabinoids as adjuvants for the accelerated induction and production of an antibody based immune response.

Disclosed are methods and compositions related to the use cannabinoids as adjuvants for the accelerated induction and production of an antibody based immune response.

Provided is a swine fever antigen fused with a porcine Fc fragment, and more particularly, to a vaccine composition having an autoimmune-enhancing effect by binding the Fc fragment to a swine fever antigen, and a preparation method thereof.

Provided is a swine fever antigen fused with a porcine Fc fragment, and more particularly, to a vaccine composition having an autoimmune-enhancing effect by binding the Fc fragment to a swine fever antigen, and a preparation method thereof.

The present disclosure provides methods for the treatment of inflammatory bowel disease (IBD) or an eosinophilic gastrointestinal disorder (EGID), such as eosinophilic esophagitis (EOE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EC). In particular, the present disclosure provides methods for the treatment of IBD or an EGID through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of IBD or an EGID.

The present invention is directed to novel vaccine delivery platform based on the Orf virus (ORFV) genome, which carry heterologous antigens, methods of making and methods of using the same for prevention of infections, diseases, and other conditions in animals.

The present invention relates to an immunoadjuvant composition that includes amphiphilic polymer particles in an oil-in-water emulsion state containing an amphiphilic poly-amino acid polymer and a method of preparing the same. Since the immunoadjuvant composition of the present invention is prepared using an amphiphilic poly-amino acid polymer, it allows the provision of a vaccine immunoadjuvant composition which is more biocompatible and has a high antibody titer.